Fig. 6.
Systemic bone anabolic action of the chalcone derivative formulations in BMP-2n/Smurf1e mice. a A schematic diagram illustrating the experimental design. 6-month-old mice were OVX and left untreated for 9 months (15-month-old) to induce osteoporosis. The mice received intravenous administration of different chalcone derivative formulations at a dose of 10.0 μmol kg–1, with an injection interval of once every three days, or daily subcutaneous injection of recombinant human parathyroid hormone (PTH, amino acids 1–34) at a dose of 40.0 μg kg–1. b Representative images showing three-dimensional trabecular architecture by microCT reconstruction at the proximal tibia. Scale bars, 500 μm. c microCT measurements for BMD and BV/TV at the proximal tibia. d Representative images showing bone formation at the proximal tibia assessed by xylenol (red) and calcein (green) labeling. Scale bar, 10 µm. e Analysis of dynamic bone histomorphometric parameters (MAR and BFR/BS) at the proximal tibia. n = 9 per group. Data are mean ± s.d. followed by one-way ANOVA with a post-hoc test